Hospital Moncloa Grupo Hla S.A.

Madrid 9 trials 6 recruiting

9 Registered trials

6 Currently recruiting

Organisation

Hospital Moncloa Grupo Hla S.A.

Location

Madrid, Spain

Identifier

ORG-100052958

Address

Avenida De Valladolid 83, 28008, Spain

Departments

Allergy
Hematología
Hematology
Oncología
Oncology
Thoracic Oncology

Clinical trials at this site (9)

Search interface

Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad… Pending

2025-521221-32-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5
A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant… Pending

2025-524241-27-00 Treatment-naїve mantle cell lymphoma (MCL) 5
A study to compare Efficacy, Safety and How the Body Absorbs, Distributes, and Eliminates of Subcutaneous CT-P44 and Darzalex Faspro in Comb… Recruiting

2024-518588-36-00 Refractory or Relapsed Multiple Myeloma 5 2025-12-24
A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-sm… Recruiting

2024-515853-48-00 advanced/metastatic non-squamous non-small cell lung ca 5 2025-09-05
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting

2025-522979-29-00 Acute myeloid leukemia 5 2026-04-30
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Newly Diagnosed Higher Risk Myelodysplastic Syndrome 5 2025-07-07
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma C… Recruiting

2024-515273-10-00 Relapsed or refractory Multiple Myeloma (r/r MM) 7 2021-10-19
Clinical trial to asses the efficacy and safety of a vaccine for grasses and cupressaceae allergy Recruiting

2024-514524-16-00 Aetiological treatment of moderate-severe intermitent o 5 2021-05-11
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Newly-diagnosed multiple myeloma (NDMM) 5 2022-10-14